Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for FPH.NZ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for FPH.NZ and 80,000+ other tickers.
See exactly how FPH.NZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FPH.NZ and 80,000+ other tickers.
Operating globally, Fisher & Paykel Healthcare Corporation Limited specializes in the development, manufacturing, and marketing of a wide array of medical device products and systems. These solutions are primarily utilized for acute and chronic respiratory care, during surgical procedures, and in the treatment of obstructive sleep apnea (OSA) within both hospital and home environments. Key offerings include the Airvo 2, a humidified nasal high flow system; Optiflow, for nasal high flow therapy; and the F&P 850 System, which facilitates noninvasive and invasive ventilation. The company also…
No recent news available.